A new path for neurodegenerative diseases
Investigación
Desarrollamos terapias génicas innovadoras para enfermedades neurodegenerativas mediante un mecanismo de acción multifuncionalA new path for neurodegenerative diseases
Equipo científico
Equipo científico integrado por investigadores con más de 30 años de experiencia en neurocienciaResearch
We’re pioneering innovative gene therapies for neurodegenerative diseases through a multifactorial mechanism of action
Pipeline
A radically new approach with a significant impact on neurodegenerative diseases
Scientific Team
A scientific team added by researchers with over 30 years of expertise in neuroscience
Tetraneuron
Tetraneuron is a biotech company focused on novel gene therapies for neurodegenerative diseases
Based in Madrid and Valencia, Tetraneuron emerges as a spin-off from the Cajal Institute, affiliated with the Spanish National Research Council (CSIC)
Nuestra historia
2023
New strategic alliances in Parkinson and aging
2022
Pre-IND meeting with the FDA
2021
Beginning of the preclinical regulatory phase
2020
Methode validation of TET-101
2019
Analysis of biological processes modulated by E2F4DN
2018
Validation of the Leading Compound
2017
Validation of the Leading Compound
2016
Identification of the Leading Compound
2015
Validation of the therapeutical target E2F4DN
2014
Beginning of the proof of concept
2013
Identification of the therapeutical target E2F4
2012
Tetraneuron was founded
Scientific research areas
Tetraneuron focuses its research on E2F4, a protein involved in regulating multiple brain pathways
We’re in the process of developing gene therapies aimed at addressing neurodegenerative conditions. These treatments have been devised to reinstate biological processes that have been impacted by the pathogenic phosphorylation of E2F4.
Multifactorial gene therapy Gene therapy
Our gene therapy based on E2F4DN is a promising approach for Alzheimer’s disease
Early diagnosis biomarker
A method to ascertain the early risk of developing Alzheimer’s disease
Neurodegenerative diseases
We introduce a profoundly innovative approach that holds the promise of transformative impact on brain health
Our team
The scientific team has members with over 30 years of experience in neuroscience, along with executives from biopharmaceutical companies as partners.
Álvaro Pascual-Leone. MD.PhD
Scientific Board Member
Teodoro del Ser. MD. PhD
Scientific Board Member
José M. Frade. PhD
Scientific Director and co-Founder
Mari Carmen Álvarez. PhD
Managing Director
Mar Municio. PhD
R&D Director
Noelia López Sánchez. PhD
Technical Director
David Mor
Board Member
Cristina Sánchez Puelles. PhD
Senior Researcher
Morgan Ramón Landrau
Researcher
Alberto Garrido
Laboratory Technician
Vanesa Cano
Laboratory Technician
Marika Russo. PhD
Strategic Advisor
Alonso Fernández Nistal, PhD
Strategic Advisor
Ángel Lucio Pereira
Strategic Advisor
Irene Camacho
PhD. Student